Accordingly, we demonstrate that DTX3L overexpression sensitizes prostate cancer cells to synthetic lethality by PARP inhibitors, highlighting that DTX3L overexpression indicates sensitivity to PARP inhibitors in cancers such as prostate cancer. This evidence concerns the gene DTX3L and prostate cancer.